CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income	$ 13,391	$ 7,194
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	25,007	23,496
Non-cash interest expense	102	99
Non-cash stock compensation expense	8,887	13,901
Non-cash income tax benefit	(538)	(2,263)
Non-cash amortization on investments	1,844	1,539
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:
Restricted cash	53,322	9,739
Accounts receivable, net	(13,538)	1,425
Pharmaceutical inventory	(5,121)	4,770
Other assets	(35,839)	(27,219)
Accounts payable and accrued liabilities	11,023	(25,887)
Medical claims payable and other medical liabilities	(38,292)	23,663
Contingent consideration	734	14,969
Tax contingencies	289	(787)
Deferred credits and other long-term liabilities	(227)	(480)
Other	34	(3)
Net cash provided by operating activities	21,078	44,156
Cash flows from investing activities:
Capital expenditures	(15,611)	(21,396)
Acquisitions and investments in businesses, net of cash acquired	(16,214)	(13,640)
Purchase of investments	(157,020)	(128,851)
Maturity of investments	144,902	92,499
Net cash used in investing activities	(43,943)	(71,388)
Cash flows from financing activities:
Payments to acquire treasury stock	(7,992)	(32,112)
Proceeds from exercise of stock options and warrants	7,784	36,900
Payments on long-term debt and capital lease obligations	(4,154)	(3,662)
Payments on contingent consideration	(2,000)
Tax benefit from exercise of stock options and vesting of stock awards	383	2,961
Other	(72)	(807)
Net cash provided by (used in) financing activities	(6,051)	3,280
Net decrease in cash and cash equivalents	(28,916)	(23,952)
Cash and cash equivalents at beginning of period	115,432	255,303
Cash and cash equivalents at end of period	86,516	$ 231,351
Non-cash investing activities:
Property and equipment acquired under capital leases	$ 1,293